Soleno Therapeutics Files 8-K Report
Ticker: SLNO · Form: 8-K · Filed: 2026-04-07T06:58:45-04:00
Sentiment: neutral
Topics: regulatory-filing, sec-filing
TL;DR
SOLENO filed an 8-K, no new info.
AI Summary
On April 7, 2026, Soleno Therapeutics Inc. filed an 8-K report detailing other events. The filing does not contain specific financial figures or new material events beyond the reporting of the filing itself.
Why It Matters
This filing indicates that Soleno Therapeutics Inc. has submitted a standard regulatory report to the SEC. It does not provide new information about the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or events.
Key Players & Entities
- SOLENO THERAPEUTICS INC (company) — Filer of the 8-K report
- 0001484565 (company) — CIK number for Soleno Therapeutics Inc.
- 2026-04-07 (date) — Filing date of the 8-K report
FAQ
What is the purpose of this 8-K filing by Soleno Therapeutics Inc.?
The 8-K filing on April 7, 2026, is categorized under Item 8.01, which pertains to 'Other Events'.
When was this 8-K filing accepted by the SEC?
The filing was accepted by the SEC on April 7, 2026, at 06:58:45.
What is the CIK number for Soleno Therapeutics Inc.?
The CIK number for Soleno Therapeutics Inc. is 0001484565.
What is the business address of Soleno Therapeutics Inc.?
The business address for Soleno Therapeutics Inc. is 100 MARINE PARKWAY, SUITE 400 REDWOOD CITY CA 94065.
What SIC code is associated with Soleno Therapeutics Inc.?
Soleno Therapeutics Inc. is associated with SIC code 2834, which represents Pharmaceutical Preparations.
Filing Stats: 687 words · 3 min read · ~2 pages · Grade level 14.9 · Accepted 2026-04-07 06:58:45
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
Filing Documents
- d141594d8k.htm (8-K) — 24KB
- 0001193125-26-144511.txt ( ) — 135KB
- slno-20260407.xsd (EX-101.SCH) — 3KB
- slno-20260407_lab.xml (EX-101.LAB) — 18KB
- slno-20260407_pre.xml (EX-101.PRE) — 11KB
- d141594d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Except for the factual statements made herein, information contained in this Current Report on Form 8-K consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects or future events, as well as words such as "believes," "intends," "expects," "plans" and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that the Company will re-engage with the EMA. Reference is also made to other factors detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K and the Company assumes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this Current Report on Form 8-K, unless required by law.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: April 7, 2026 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer